KPV
Also known as: Lys-Pro-Val, Alpha-MSH fragment, KPV tripeptide, Anti-inflammatory tripeptide
KPV is a naturally-occurring tripeptide derived from the C-terminus of alpha-melanocyte stimulating hormone (α-MSH), demonstrating potent anti-inflammatory effects independent of melanocortin receptor activation.
KPV Overview & Molecular Profile
KPV represents the minimal anti-inflammatory sequence of alpha-melanocyte stimulating hormone, consisting of just three amino acids: lysine-proline-valine. Unlike the parent α-MSH molecule, KPV does not activate melanocortin receptors and therefore does not produce tanning or appetite effects, while retaining powerful anti-inflammatory and antimicrobial properties. The peptide has attracted significant research interest for inflammatory bowel disease, wound healing, and skin conditions due to its favorable safety profile and multi-mechanistic anti-inflammatory activity. Research has demonstrated efficacy in various inflammatory models including colitis, arthritis, and dermatitis, with particular focus on gut inflammation where KPV may be delivered orally or locally. The tripeptide structure offers advantages for formulation and stability compared to larger anti-inflammatory peptides.
Mechanism of Action: Immunomodulation & Antimicrobial Activity
KPV exerts anti-inflammatory effects through multiple receptor-independent mechanisms that distinguish it from the parent α-MSH molecule. The peptide enters cells and directly inhibits inflammatory signaling pathways, particularly NF-κB activation and subsequent inflammatory cytokine production. Research demonstrates inhibition of IκB kinase and preservation of IκBα, preventing NF-κB nuclear translocation. KPV also modulates the inflammasome pathway, reducing IL-1β and IL-18 production. Additional mechanisms include inhibition of MAPK signaling pathways, reduction of reactive oxygen species, and modulation of immune cell function including reduced neutrophil activation and macrophage inflammatory polarization. The peptide may also exert direct antimicrobial effects independent of immune modulation.
Research-Observed Effects
Anti-inflammatory Activity
Extensive research demonstrates KPV produces profound anti-inflammatory effects across multiple experimental models without the immunosuppression associated with corticosteroids. Studies document significant inhibition of pro-inflammatory cytokines including TNF-alpha, IL-1beta, IL-6, and IL-8 in various cell types and tissues. The peptide reduces NF-κB nuclear translocation by up to 80% in some models, blocking the master inflammatory transcription pathway. Research shows decreased inflammatory cell infiltration, reduced tissue edema, and accelerated resolution of inflammation. Unlike melanocortin receptor agonists, KPV's effects are not blocked by melanocortin receptor antagonists, confirming receptor-independent mechanisms. Studies indicate potential applications in chronic inflammatory conditions, autoimmune diseases, and inflammatory tissue damage.
Inflammatory Bowel Disease Research
Preclinical studies demonstrate significant efficacy in experimental colitis models, with KPV reducing disease activity scores, improving histological inflammation, and promoting mucosal healing. The peptide can be administered orally with demonstrated efficacy, suggesting stability in the gastrointestinal environment and potential for targeted gut delivery. Research documents reduced inflammatory cytokine expression in colonic tissue, decreased neutrophil infiltration, and improved barrier function. Studies in both acute and chronic colitis models show therapeutic benefit when administered either prophylactically or after disease onset. The combination of anti-inflammatory and potential antimicrobial effects may address multiple aspects of IBD pathophysiology. Clinical development is being explored for ulcerative colitis and Crohn's disease applications.
Wound Healing Enhancement
Research demonstrates KPV accelerates wound healing through a combination of anti-inflammatory effects and direct promotion of tissue repair processes. Studies document enhanced keratinocyte migration, improved re-epithelialization rates, and reduced scar formation in various wound models. The peptide modulates the inflammatory phase of wound healing, preventing excessive inflammation while maintaining beneficial immune responses needed for debris clearance and infection control. Research shows improvements in chronic and diabetic wound healing models where excessive inflammation impairs normal repair. Topical KPV formulations have shown efficacy in skin wound studies, and the peptide is being investigated for combination with other wound healing compounds.
Antimicrobial Properties
Studies reveal KPV possesses direct antimicrobial activity against various bacteria, fungi, and even some viruses, independent of its immunomodulatory effects. Research documents activity against gram-positive and gram-negative bacteria including drug-resistant strains, with mechanisms involving membrane disruption and interference with microbial energy metabolism. The peptide has shown activity against Candida species and other pathogenic fungi. The dual anti-inflammatory and antimicrobial properties are particularly valuable for infected wound applications and inflammatory conditions with microbial components. Studies suggest potential synergy with conventional antibiotics and applications in antimicrobial resistance research.
Neuroprotective Potential
Emerging research suggests KPV may provide neuroprotective effects through suppression of neuroinflammation, a key driver of neurodegenerative diseases. Studies in CNS inflammation models demonstrate reduced microglial activation, decreased pro-inflammatory cytokine production in brain tissue, and protection against oxidative stress. Research indicates KPV can cross the blood-brain barrier to some extent, enabling central effects following systemic administration. Preclinical studies show potential benefits in models of stroke, traumatic brain injury, and neurodegeneration. The anti-inflammatory mechanism aligns with growing recognition of neuroinflammation's role in Alzheimer's disease, Parkinson's disease, and other CNS conditions.
Research Dosing Information
Research studies have used various routes and doses depending on the application. Oral administration for IBD research has utilized doses ranging from 200 mcg to 2 mg in animal models. Topical formulations for wound and skin applications have used concentrations of 0.001% to 0.1%. Intraperitoneal and subcutaneous routes have been employed in systemic inflammation studies. The optimal dosing for human applications remains under investigation.
Note: Dosing information is provided for research reference only and is based on published studies using research subjects. This is not a recommendation for any use.
Research Studies & References
KPV tripeptide reduces intestinal inflammation in experimental colitis through NF-κB inhibition
Dalmasso G, Charrier-Hisamuddin L, et al. (2008). Gastroenterology
This foundational study investigated KPV's anti-inflammatory mechanisms and therapeutic efficacy in experimental colitis. Using DSS and TNBS-induced colitis models, researchers demonstrated that oral KPV significantly reduced disease activity, histological inflammation scores, and colonic cytokine expression. Mechanistic experiments revealed KPV inhibited NF-κB activation by preventing IκBα degradation in intestinal epithelial cells and immune cells. The study documented reduced myeloperoxidase activity (marker of neutrophil infiltration) and improved epithelial barrier function. Importantly, KPV remained effective when administered orally, suggesting gastrointestinal stability and potential for practical IBD treatment. These results established the scientific foundation for KPV's development as a therapeutic candidate for inflammatory bowel disease.
Alpha-MSH tripeptide KPV promotes wound healing through anti-inflammatory and antimicrobial mechanisms
Bonfiglio V, Camillieri G, et al. (2014). Journal of Dermatological Science
This comprehensive study evaluated KPV's effects on wound healing using in vitro and in vivo models. Researchers demonstrated that topical KPV accelerated wound closure rates by 40% compared to controls, with enhanced keratinocyte migration and reduced inflammatory cell infiltration. The study documented direct antimicrobial activity against wound-relevant pathogens including Staphylococcus aureus and Pseudomonas aeruginosa. Histological analysis revealed improved granulation tissue formation and reduced scarring in KPV-treated wounds. The combination of anti-inflammatory and antimicrobial effects positioned KPV as a multi-functional wound healing agent. These findings support development of KPV-containing formulations for chronic wound management and post-surgical healing applications.
Anti-inflammatory tripeptide KPV suppresses neuroinflammation in CNS disease models
Kannengiesser K, Maaser C, et al. (2011). Journal of Neuroinflammation
This study investigated KPV's potential for modulating neuroinflammation, a key pathological process in neurodegenerative diseases. Using LPS-stimulated microglial cultures and experimental neuroinflammation models, researchers demonstrated KPV significantly reduced pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6) and decreased microglial activation markers. The study documented BBB penetration sufficient for central effects following systemic administration. In vivo experiments showed reduced brain inflammatory markers and improved behavioral outcomes in neuroinflammation models. Mechanistic analysis confirmed NF-κB inhibition as the primary pathway for neuroprotective effects. These findings suggest potential applications for KPV in neurodegenerative disease research and CNS inflammatory conditions.
Comparative Research
Explore in-depth research analyses and comparative studies featuring KPV.
Frequently Asked Questions
BPC-157
C62H98N16O22
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. It has been extensively studied for its potential regenerative and protective properties in various tissue types.
LL-37
C205H340N60O53
LL-37 is a human cathelicidin antimicrobial peptide that plays a crucial role in innate immunity. It has broad-spectrum antimicrobial activity and immunomodulatory properties.
Thymosin Alpha-1
C129H215N33O55
Thymosin Alpha-1 is a peptide originally isolated from thymic tissue that modulates immune function. It is approved in several countries for immune deficiency conditions and as an adjuvant therapy.